Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 19, Issue SUPPL. 2, 2008, Pages

  Stupp, R ^a,c   Roila, F ^b,c  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYTOTOXIC AGENT; ERLOTINIB; LOMUSTINE; NITROSOUREA; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ADJUVANT THERAPY; ARTICLE; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL TRIAL; DRUG RESPONSE; DRUG TREATMENT FAILURE; GLIOBLASTOMA; HUMAN; LABORATORY TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL TIME; TREATMENT PLANNING; TREATMENT RESPONSE; BRAIN TUMOR; FOLLOW UP; GLIOMA; PATHOLOGY; PRACTICE GUIDELINE; TUMOR RECURRENCE;

BRAIN NEOPLASMS; FOLLOW-UP STUDIES; GLIOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGODENDROGLIOMA;

EID: 45149128136     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn099     Document Type: Article

References (24)

1. Brandes AA, Tosoni A, Basso U et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: A phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 2004; 22: 4727-4734.
2. Cairncross G, Berkey B, Shaw E et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006; 24: 2707-2714.
3. DeAngelis LM. Medical progress: Brain tumors. N Engl J Med 2001; 344: 114-123.
4. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
5. Jaeckle KA, Ballman KV, Rao RD et al. Current strategies in treatment of oligodendroglioma: Evolution of molecular signatures of response. J Clin Oncol 2006; 24: 1246-1252.
6. Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007; 356: 1527-1535.
7. Kleihues P, Louis DN, Scheithauer BW et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61: 215-225.
8. Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 2001; 95: 190-198.
9. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-1280.
10. Medical Research Council Brain Tumor Working Party. Randomized trial of procarbazine, lomustine and vincristine in the adjuvant treatment of high-grade astrocytomaa Medical Research Council trial. J Clin Oncol 2001; 19: 509-518.
11. Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: A prospective randomized clinical trial. J Clin Oncol 2004; 22: 1583-1588.
12. Stewart LA. Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359: 1011-1018.
13. Stummer W, Pichlmeier U, Meinel T et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7: 392-401.
14. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: Standard of care and future directions. J Clin Oncol 2007; 25: 4127-4136.
15. Stupp R, Hegi ME, van den Bent MJ et al. Changing paradigms - an update of the multidisciplinary management of malignant glioma. Oncologist 2006; 11: 165-180.
16. Stupp R, Mason WP, van den Bent MJ et al. Concomitant and adjuvant temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme. N Engl J Med 2005; 352: 987-996.
17. van den Bent M, Brandes A, Rampling R et al. Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme: EORTC 26034. ASCO Ann Meet Proc Part I. J Clin Oncol 2007; 25: 76S (Abstr 2004).
18. van den Bent MJ, Carpenter AF, Brandes AA et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organization for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006; 24: 2715-2722.
19. van den Bent MJ, Taphoorn MJ, Brandes AA et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003; 21: 2525-2528.
20. Westphal M, Hilt DC, Bortey E et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 2003; 5: 79-88.
21. Westphal M, Ram Z, Riddle V et al. Gliadel wafer in initial surgery for malignant glioma: Long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006; 148: 269-275.
22. Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999; 17: 2572-2578.
23. Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: A computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 1988; 6: 338-343.
24. Yung WK, Albright RE, Olson J et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83: 588-593.